ImmunoGen, Inc. Announces Webcast of Presentation at the J.P. Morgan 30th Annual Healthcare Conference
January 03 2012 - 1:00PM
ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that
develops targeted antibody-based anticancer products, today
announced that its presentation at the J.P. Morgan 30th Annual
Healthcare Conference at 2:00 pm PT on January 10, 2012 will be
webcast live.
The webcast of this presentation can be accessed live through
the "Investor Information" section of the Company's website,
www.immunogen.com; a replay of the presentation will be available
at the same location for two weeks.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company's expertise in tumor biology, monoclonal antibodies,
potent cancer-cell killing agents and engineered linkers. The
Company's Targeted Antibody Payload (TAP) technology uses
monoclonal antibodies to deliver one of ImmunoGen's proprietary
cancer-cell killing agents specifically to tumor cells. There are
now numerous TAP compounds in clinical development with a wealth of
clinical data reported. ImmunoGen's collaborative partners include
Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Lilly, Novartis,
Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP
technology, trastuzumab emtansine (T-DM1), is in Phase III testing
through the Company's collaboration with Genentech, a member of the
Roche Group. More information about ImmunoGen can be found at
www.immunogen.com.
CONTACT: For Investors:
Carol Hausner
Executive Director, Investor Relations and
Corporate Communications
ImmunoGen, Inc.
(781) 895-0600
info@immunogen.com
For Media:
Barbara Yates
The Yates Network
(781) 258-6153
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024